Results 211 to 220 of about 44,321 (338)

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma [PDF]

Eric M. Jurgens, Tala Shekarkhand, Tasmin Farzana, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross Firestone, Noriko Nishimura, Kevin Miller, Bruno Almeida Costa, Karthik Nath, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam S. Hamadeh, Sergio Giralt, David J. Chung, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Saad Z. Usmani, Sham Mailankody, Zainab Shahid   +28 more
openalex   +1 more source

A Generalized Minimal PBPK‐PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bispecific antibodies (bsAbs), for which each arm binds a distinct molecular target, are developed to engage soluble and cell surface targets in different therapeutic indications. Three key examples of mechanisms of action (MoA) for bsAbs are (1) immune cell engagers that foster immune cell interactions with target cells, (2) bispecifics that ...
Phillip Spinosa, Louis Joslyn, Saroja Ramanujan, Kapil Gadkar, Iraj Hosseini   +4 more
wiley   +1 more source

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. [PDF]

BioDrugs
Shastri T, Trabolsi A, Arumov A, Schatz JH.   +3 more
europepmc   +1 more source

Bispecific Antibody MDX447 [PDF]

, 2020
openaire   +1 more source

Supplementary Figure S9 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade

Hampus Andersson, Ida Uddbäck, Tova Hermodsson, Mona Celander, Amulya Krishna Shetty, Lill Ljung, Anneli Nilsson, Anette Sundstedt, Laura von Schantz, Laura A. Varas, Mattias Levin, Anna Säll, Dietmar Weilguny, K. Jansson, Sara Fritzell, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark   +17 more
openalex   +1 more source

Quantitative Prediction of Human Pharmacokinetics for Fc‐Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Fc‐engineered antibodies (mAbs) enhancing FcRn binding have rapidly expanded in drug discovery and development. Although an approach exists for predicting the pharmacokinetics of Fc‐engineered mAbs after intravenous injections in humans, no methodology has been established for predicting pharmacokinetics after subcutaneous injections.
Kenta Haraya, Taichi Kuramochi
wiley   +1 more source

Toxicities associated with lymphoma-targeting bispecific antibodies-a review. [PDF]

Front Med (Lausanne)
Doig C, Yannakou CK.
europepmc   +1 more source

Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies

Tarek Nahle, Viraj Shah, Sami Abi Farraj, Ali Atoui   +3 more
openalex   +2 more sources

Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management

European Journal of Haematology, Volume 116, Issue 2, Page 116-128, February 2026.
ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli, E. Carazzai, B. Bugnotto, F. Bellinato, M. Krampera, C. Visco   +5 more
wiley   +1 more source

Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies. [PDF]

Int J Mol Sci
Yang HM.
europepmc   +1 more source